Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition

被引:24
作者
Yang, Jiansong
Jamei, Masoud
Yeo, Karen Rowland
Tucker, Geoffrey T.
Rostami-Hodjegan, Amin
机构
[1] Simcyp Ltd, Blades Enterprise Ctr, Sheffield S2 4SU, S Yorkshire, England
[2] Univ Sheffield, Acad Unit Clin Pharmacol, Pharmacokinet & Pharmacogenet Grp, Sheffield, S Yorkshire, England
关键词
mechanism-based inhibition; enzyme inactivation; drug interactions; simulation; genetic algorithm;
D O I
10.1016/j.ejps.2007.04.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We have shown previously that the conventional experimental protocol (CEP) used to characterise mechanism-based enzyme inhibition (MBI) of drug metabolism in vitro may introduce substantial bias in estimates of the relevant kinetic parameters. The aim of this study was to develop and assess, by computer simulation, an alternative, mechanistically-based experimental protocol (MEP). This protocol comprises three parts viz. assessment of the metabolism of the mechanism-based enzyme inactivator (MBEI), of its ability to participate in competitive inhibition and its ability to cause time-dependent inhibition. Thus, values of the maximum inactivation rate constant (k(inact)), the inactivator concentration associated with half-maximal rate of inactivation (K-I), the partition ration (r), and the reversible inhibition constant (K-i) of the MBEI are determined by nonlinear optimization of the experimental data using a model that allows for metabolism of both probe substrate and MBEI, the time-course of inactivation of the enzyme, and reversible inhibition of the metabolism of both probe substrate and MBEI. Sensitivity analysis is used to estimate the degree of confidence in the final parameter values. Virtual experiments using the MEP and the CEP were simulated, applying starting kinetic parameters reported for 16 known MBEIs. In the presence of simulated experimental error (5% CV), the MEP recovered accurate estimates of the kinetic values for all compounds, while estimates using the CEP were less accurate and less precise. The MEP promises to improve consistency in the determination of in vitro measures of MBI and, thereby, the quantitative assessment of its in vivo consequences. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:232 / 241
页数:10
相关论文
共 49 条
[1]  
[Anonymous], 2006, GUID IND DRUG INT ST
[2]   Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis [J].
Atkinson, A ;
Kenny, JR ;
Grime, K .
DRUG METABOLISM AND DISPOSITION, 2005, 33 (11) :1637-1647
[3]   Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine [J].
Bertelsen, KM ;
Venkatakrishnan, K ;
Von Moltke, LL ;
Obach, RS ;
Greenblatt, DJ .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (03) :289-293
[4]   A genetic algorithm-based, hybrid machine learning approach to model selection [J].
Bies, RR ;
Muldoon, MF ;
Pollock, BG ;
Manuck, S ;
Smith, G ;
Sale, ME .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2006, 33 (02) :195-221
[5]   The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective [J].
Bjornsson, TD ;
Callaghan, JT ;
Einolf, HJ ;
Fischer, V ;
Gan, L ;
Grimm, S ;
Kao, J ;
King, SP ;
Miwa, G ;
Ni, L ;
Kumar, G ;
McLeod, J ;
Obach, RS ;
Roberts, S ;
Roe, A ;
Shah, A ;
Snikeris, F ;
Sullivan, JT ;
Tweedie, D ;
Vega, JM ;
Walsh, J ;
Wrighton, SA .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (07) :815-832
[6]   Prediction of aqueous solubility of organic compounds using a quantitative structure-property relationship [J].
Chen, XQ ;
Cho, SJ ;
Li, Y ;
Venkatesh, S .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (08) :1838-1852
[7]  
Chiba M, 1995, J PHARMACOL EXP THER, V275, P1527
[8]  
Chun J, 2000, DRUG METAB DISPOS, V28, P905
[9]   Mechanism-based inactivation of cytochrome P4502B6 by a novel terminal acetylene inhibitor [J].
Fan, PW ;
Gu, CG ;
Marsh, SA ;
Stevens, JC .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (01) :28-36
[10]  
Favreau LV, 1999, DRUG METAB DISPOS, V27, P436